Skip to main content

Athersys could raise an additional $12.8M from unnamed institutional investor

For months, Athersys has been restructuring its operations and trying to raise the cash it needs to complete the testing and commercialization of its adult stem cell therapy.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.